Developer docs
API playgroundTry for free, no card

Search company profiles

Advanced Bionics

Full company profile

uuid0007dwk

Namestring
Advanced Bionics
Legal namestring
Advanced Bionics, LLC
Company typeenum
Private
Founded yearint
1993
Descriptiontext

Advanced Bionics is a global manufacturer of cochlear implant systems for individuals with severe-to-profound hearing loss, operating as a wholly-owned subsidiary of Swiss hearing solutions conglomerate Sonova AG since its 2009 acquisition. Founded in 1993 and headquartered operationally in Valencia, California with legal domicile in Stäfa, Switzerland, the company employs over 800 people and has implanted more than 50,000 adults and children worldwide with its devices.

The product portfolio consists of an internal cochlear implant (HiRes Ultra 3D, MRI-compatible) paired with external sound processors differentiated by patient population: the Naída CI Marvel for adults and the Sky CI M, marketed as the world's first processor designed specifically for pediatric recipients. Core enabling technologies include multi-channel electrical stimulation of the auditory nerve, advanced sound processing algorithms, universal Bluetooth connectivity for hands-free calling and audio streaming, waterproof/shockproof/dustproof housing, and remote programming via telehealth. A notable differentiator is bimodal integration with sister brand Phonak hearing aids, enabling linked two-ear solutions unavailable from standalone competitors Cochlear Ltd. and Med-El.

The business model rests on three revenue streams: hardware sales of implant systems and sound processors, professional services including fitting, programming, and ongoing clinical support, and recurring upgrade and accessory sales to existing recipients. Distribution is almost entirely clinical, routed through audiologists, ENT surgeons, and hearing clinics, supplemented by a direct patient contact center, telehealth remote programming, and Sonova Group's global infrastructure reaching more than 100 countries. Pricing is quote-based and largely covered by Medicare and private insurance rather than direct out-of-pocket payment.

Short descriptiontext

Advanced Bionics is a Sonova-owned manufacturer of cochlear implant systems for adults and children with severe-to-profound hearing loss, selling MRI-compatible implants, sound processors, and Phonak-integrated bimodal solutions through clinical channels globally.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1,001–5,000
akta.pro rankint
HeadquartersSanta Clarita, United States
HQ citystring
Santa Clarita
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
cochlear implants, hearing implants, sound processors, implantable neurostimulation, bimodal hearing solutions
Industry1 code
PRIMARYCRACANAL
Hearing Enhancement / Assistive Listening Audio Devices
Consumer Products & Retail/Consumer Electronics & Appliances Retail/Audio & Headphones (Speakers, Earbuds, Home Audio)
NAICS code1 code
  • Electromedical and Electrotherapeutic Apparatus Manufacturing334510
SIC code1 code
  • Electromedical & Electrotherapeutic Apparatus3845
Product category
Cochlear Implants
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model3 records
1Cochlear Implant Hardware Sales
TypeHardware Sales
Description

Sale of cochlear implant devices (internal components) and external sound processors to patients and healthcare providers. The devices are implanted through surgery and require the purchase of the implant system and ongoing processor upgrades.

advancedbionics.com
2Professional Services and After-Sales Support
TypeProfessional Services
Description

Ongoing programming, fitting, adjustment, and support services for cochlear implant recipients. Includes telehealth/remote programming capabilities and insurance support services.

advancedbionics.com
3Upgrade and Accessory Sales
TypeHardware Sales
Description

Sale of replacement processors, accessories, color options, and upgrade opportunities for existing implant recipients.

advancedbionics.com
Marketing channels8 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Technology or R&D, Supply Chain, Operations, Personnel, Marketing or Sales, Infrastructure
Pricing details1 tier
1Cochlear implant systems — device pricing not publicly disclosed, covered by insurance
ModelOtherBilling cadenceMulti-year contract
Notes

Cochlear implant systems are custom medical devices with pricing determined through clinical consultation and insurance verification. Medicare and many private insurance plans provide coverage. Contact the insurance support team for cost estimates.

advancedbionics.com
GTM typeB2C
B2C
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Advanced Bionics develops and manufactures cochlear implant systems consisting of an internally implanted electrode array (such as the HiRes Ultra 3D) and externally worn sound processors (Naída CI Marvel for adults, Sky CI M for children). The implants bypass damaged hair cells to directly stimulate the auditory nerve for individuals with severe-to-profound hearing loss, supported by remote programming, fitting tools, and digital care services.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • 90% increase in speech understanding with a cochlear implant
+2 more records
Product overview1 text field

Advanced Bionics is a global manufacturer of cochlear implant technology and hearing solutions, operating as a subsidiary of Sonova Group and sister brand to Phonak hearing aids. The company's product portfolio centers on cochlear implants for severe-to-profound hearing loss, comprising internally-implanted electrode devices (such as the HiRes Ultra 3D Cochlear Implant) and externally-worn sound processors. Current-generation processors include the Naída CI Marvel for adults and Sky CI M for children. Key enabling technologies include Bluetooth wireless connectivity for audio streaming, waterproof housing, remote programming telehealth capabilities, and bimodal integration with Phonak hearing aids. The company serves both pediatric and adult populations, with over 50,000 implant recipients reported.

Product and service1 record
1Naída CI Marvel Sound Processor
Scale indicator10 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2026-04-15
Description

Advanced Bionics announced an equity investment and research collaboration with Spiral Therapeutics to explore integrating Spiral's drug-delivery platform with AB's cochlear implant development. The partnership focuses on investigating minimally invasive and precise delivery of therapeutics to the cochlea during cochlear implant surgery to address unmet needs in the field. The collaboration represents an early-stage R&D effort combining both companies' complementary capabilities for potential future patient benefits.

Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

A leading cochlear implant manufacturer headquartered in Austria, competing head-to-head with Advanced Bionics in CI hardware, sound processors, and surgical-channel distribution. Comparable on product, customer segments, and global direct-to-clinic GTM model.

TypeDirect peer
Description

The global market-leader in cochlear implants with the largest installed base and surgeon relationships. Compares directly to Advanced Bionics on product category (CI systems), target customers (severe-to-profound hearing loss patients, audiologists, ENT surgeons), and business model (implant hardware + sound processor + services).

TypeBroad incumbent
Description

Danish hearing-solutions parent of Oticon Medical and the Oticon hearing-aid brand. Demant competes with Sonova/Phonak/AB across both hearing aids and cochlear implants, making it a broad incumbent peer in the same end-market with overlapping clinical channels.

TypeBroad incumbent
Description

US-based hearing-aid manufacturer with custom and consumer hearing products. Although Starkey does not produce cochlear implants, it competes indirectly for audiologist mind-share and patient hearing-loss budgets that Advanced Bionics also targets.

TypeBroad incumbent
Description

Singapore-headquartered hearing-aid conglomerate formed from Siemens Hearing (Signia) and Widex. Comparable as a broad incumbent in hearing-care distribution and clinical channels that audiologists and ENT surgeons share with cochlear-implant workflows.

TypeBroad incumbent
Description

Owner of ReSound and Beltone hearing-aid brands. GN Hearing does not manufacture cochlear implants but operates in the same hearing-care clinical channel and end-patient population served by Advanced Bionics, making it a broad incumbent peer for distribution and patient overlap.

TypeBroad incumbent
Description

Advanced Bionics' sister brand under the Sonova parent and the world's leading hearing-aid manufacturer. Phonak is the integration partner for AB's bimodal solutions and shares the same corporate owner; comparable on hearing-loss end-market though Phonak's core product is amplification rather than implants.

TypeDirect peer
Description

Oticon Medical, part of Demant Group, manufactures cochlear implants and bone-anchored hearing systems. Directly comparable as a CI manufacturer selling into ENT/audiology channels; bone-anchored systems are an adjacent category Advanced Bionics has not historically contested.

9Envoy Medical
TypeEmerging player
Description

Pre-revenue/early-commercial-stage US company developing fully implanted (versus external-processor) hearing implants, including the Esteem active middle-ear implant. Comparable as a next-generation hearing-implant player pursuing a different technological pathway that could eventually overlap with AB's CI category.

TypeOthers
Description

Biotech R&D partner of Advanced Bionics focused on drug-delivery platforms for the inner ear. Included as an adjacent/partner peer because AB's April 2026 equity investment and collaboration creates a co-development relationship that may yield drug-eluting CI products.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability1 record

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature8 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles4 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment1 record

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Advanced Bionics

Cochlear Implantsadvancedbionics.com

Advanced Bionics is a Sonova-owned manufacturer of cochlear implant systems for adults and children with severe-to-profound hearing loss, selling MRI-compatible implants, sound processors, and Phonak-integrated bimodal solutions through clinical channels globally.

What Advanced Bionics does

Advanced Bionics is a global manufacturer of cochlear implant systems for individuals with severe-to-profound hearing loss, operating as a wholly-owned subsidiary of Swiss hearing solutions conglomerate Sonova AG since its 2009 acquisition. Founded in 1993 and headquartered operationally in Valencia, California with legal domicile in Stäfa, Switzerland, the company employs over 800 people and has implanted more than 50,000 adults and children worldwide with its devices.

The product portfolio consists of an internal cochlear implant (HiRes Ultra 3D, MRI-compatible) paired with external sound processors differentiated by patient population: the Naída CI Marvel for adults and the Sky CI M, marketed as the world's first processor designed specifically for pediatric recipients. Core enabling technologies include multi-channel electrical stimulation of the auditory nerve, advanced sound processing algorithms, universal Bluetooth connectivity for hands-free calling and audio streaming, waterproof/shockproof/dustproof housing, and remote programming via telehealth. A notable differentiator is bimodal integration with sister brand Phonak hearing aids, enabling linked two-ear solutions unavailable from standalone competitors Cochlear Ltd. and Med-El.

The business model rests on three revenue streams: hardware sales of implant systems and sound processors, professional services including fitting, programming, and ongoing clinical support, and recurring upgrade and accessory sales to existing recipients. Distribution is almost entirely clinical, routed through audiologists, ENT surgeons, and hearing clinics, supplemented by a direct patient contact center, telehealth remote programming, and Sonova Group's global infrastructure reaching more than 100 countries. Pricing is quote-based and largely covered by Medicare and private insurance rather than direct out-of-pocket payment.

Advanced Bionics firmographics

Firmographics
Name
Advanced Bionics
Legal name
Advanced Bionics, LLC
Website
https://advancedbionics.com
Company type
Private
Founded year
1993
Operating status
Operating
Headcount range
1,001–5,000 employees
Short description
Advanced Bionics is a Sonova-owned manufacturer of cochlear implant systems for adults and children with severe-to-profound hearing loss, selling MRI-compatible implants, sound processors, and Phonak-integrated bimodal solutions through clinical channels globally.
Ownership category
akta.pro rank

Advanced Bionics industry classification

Industry
Product category
Cochlear Implants
NAICS
Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)
SIC
Electromedical & Electrotherapeutic Apparatus (3845)
akta.pro industry
PRIMARYCRACANAL
Hearing Enhancement / Assistive Listening Audio Devices
Consumer Products & Retail/Consumer Electronics & Appliances Retail/Audio & Headphones (Speakers, Earbuds, Home Audio)

Keywords

  • Cochlear implants
  • Hearing implants
  • Sound processors
  • Implantable neurostimulation
  • Bimodal hearing solutions

Where Advanced Bionics is headquartered

Location

Headquarters

HQ city
Santa Clarita
HQ country
United States
HQ region
North America

Offices3 records

Markets served

Advanced Bionics business model

Business model
GTM type
B2C
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Supply Chain, Operations, Personnel, Marketing or Sales, Infrastructure

Revenue model

  1. Cochlear Implant Hardware Sales: Sale of cochlear implant devices (internal components) and external sound processors to patients and healthcare providers. The devices are implanted through surgery and require the purchase of the implant system and ongoing processor upgrades.
  2. Professional Services and After-Sales Support: Ongoing programming, fitting, adjustment, and support services for cochlear implant recipients. Includes telehealth/remote programming capabilities and insurance support services.
  3. Upgrade and Accessory Sales: Sale of replacement processors, accessories, color options, and upgrade opportunities for existing implant recipients.

Pricing tiers

ModelBillingPrice
OtherMulti-year contractCochlear implant systems — device pricing not publicly disclosed, covered by insurance

Go-to-market motion2 records

Distribution channels4 records

Marketing channels8 records

Advanced Bionics product offering

Product offering

Core offering

Advanced Bionics develops and manufactures cochlear implant systems consisting of an internally implanted electrode array (such as the HiRes Ultra 3D) and externally worn sound processors (Naída CI Marvel for adults, Sky CI M for children). The implants bypass damaged hair cells to directly stimulate the auditory nerve for individuals with severe-to-profound hearing loss, supported by remote programming, fitting tools, and digital care services.

Product overview

Advanced Bionics is a global manufacturer of cochlear implant technology and hearing solutions, operating as a subsidiary of Sonova Group and sister brand to Phonak hearing aids. The company's product portfolio centers on cochlear implants for severe-to-profound hearing loss, comprising internally-implanted electrode devices (such as the HiRes Ultra 3D Cochlear Implant) and externally-worn sound processors. Current-generation processors include the Naída CI Marvel for adults and Sky CI M for children. Key enabling technologies include Bluetooth wireless connectivity for audio streaming, waterproof housing, remote programming telehealth capabilities, and bimodal integration with Phonak hearing aids. The company serves both pediatric and adult populations, with over 50,000 implant recipients reported.

Differentiator

Problem solved

Functional benefit

Products and services

  • Naída CI Marvel Sound Processor

Quantifiable outcome

  • 90% increase in speech understanding with a cochlear implant
  • +2 more outcomes

Companies that use Advanced Bionics

Customer profile

Named customers2 records

Segments3 records

Ideal customer profiles3 records

Advanced Bionics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability1 record

Feature8 records

Advanced Bionics partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • Spiral TherapeuticsminorStrategic or Co-development Partner · 15 April 2026Advanced Bionics announced an equity investment and research collaboration with Spiral Therapeutics to explore integrating Spiral's drug-delivery platform with AB's cochlear implant development. The partnership focuses on investigating minimally invasive and precise delivery of therapeutics to the cochlea during cochlear implant surgery to address unmet needs in the field. The collaboration represents an early-stage R&D effort combining both companies' complementary capabilities for potential future patient benefits.

Scale indicators10 records

Recent moves8 records

Expansion highlights6 records

Advanced Bionics competitors and assessment

Company assessment

Direct peers

  • MED-EL: A leading cochlear implant manufacturer headquartered in Austria, competing head-to-head with Advanced Bionics in CI hardware, sound processors, and surgical-channel distribution. Comparable on product, customer segments, and global direct-to-clinic GTM model.
  • Cochlear Limited: The global market-leader in cochlear implants with the largest installed base and surgeon relationships. Compares directly to Advanced Bionics on product category (CI systems), target customers (severe-to-profound hearing loss patients, audiologists, ENT surgeons), and business model (implant hardware + sound processor + services).
  • Oticon Medical (Demant): Oticon Medical, part of Demant Group, manufactures cochlear implants and bone-anchored hearing systems. Directly comparable as a CI manufacturer selling into ENT/audiology channels; bone-anchored systems are an adjacent category Advanced Bionics has not historically contested.

Broad incumbents

  • Demant: Danish hearing-solutions parent of Oticon Medical and the Oticon hearing-aid brand. Demant competes with Sonova/Phonak/AB across both hearing aids and cochlear implants, making it a broad incumbent peer in the same end-market with overlapping clinical channels.
  • Starkey Hearing Technologies: US-based hearing-aid manufacturer with custom and consumer hearing products. Although Starkey does not produce cochlear implants, it competes indirectly for audiologist mind-share and patient hearing-loss budgets that Advanced Bionics also targets.
  • WS Audiology (Signia / Widex): Singapore-headquartered hearing-aid conglomerate formed from Siemens Hearing (Signia) and Widex. Comparable as a broad incumbent in hearing-care distribution and clinical channels that audiologists and ENT surgeons share with cochlear-implant workflows.
  • GN Hearing (GN Audio): Owner of ReSound and Beltone hearing-aid brands. GN Hearing does not manufacture cochlear implants but operates in the same hearing-care clinical channel and end-patient population served by Advanced Bionics, making it a broad incumbent peer for distribution and patient overlap.
  • Phonak (Sonova): Advanced Bionics' sister brand under the Sonova parent and the world's leading hearing-aid manufacturer. Phonak is the integration partner for AB's bimodal solutions and shares the same corporate owner; comparable on hearing-loss end-market though Phonak's core product is amplification rather than implants.

Emerging players

  • Envoy Medical: Pre-revenue/early-commercial-stage US company developing fully implanted (versus external-processor) hearing implants, including the Esteem active middle-ear implant. Comparable as a next-generation hearing-implant player pursuing a different technological pathway that could eventually overlap with AB's CI category.

Others

  • Spiral Therapeutics: Biotech R&D partner of Advanced Bionics focused on drug-delivery platforms for the inner ear. Included as an adjacent/partner peer because AB's April 2026 equity investment and collaboration creates a co-development relationship that may yield drug-eluting CI products.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

Advanced Bionics social profiles

Digital presence

Advanced Bionics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Advanced Bionics leadership team

Management profile

Number of profiles

Profiles4 records

Advanced Bionics funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Advanced Bionics M&A and investment

M&A and investment

M&A

Investments1 record

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Advanced Bionics

What does Advanced Bionics do?

Advanced Bionics develops and manufactures cochlear implant systems consisting of an internally implanted electrode array (such as the HiRes Ultra 3D) and externally worn sound processors (Naída CI Marvel for adults, Sky CI M for children). The implants bypass damaged hair cells to directly stimulate the auditory nerve for individuals with severe-to-profound hearing loss, supported by remote programming, fitting tools, and digital care services.

Is Advanced Bionics a public or private company?

Advanced Bionics is a private company. It is classified as corporate owned and is currently operating.

When was Advanced Bionics founded?

Advanced Bionics was founded in 1993. It employs 1,001 to 5,000 people.

Where is Advanced Bionics based?

Advanced Bionics is headquartered in Santa Clarita, United States, in the North America region.

How does Advanced Bionics make money?

Three revenue lines are on record. Cochlear Implant Hardware Sales are the primary driver. The others are professional Services and After-Sales Support and upgrade and Accessory Sales.

Who are Advanced Bionics's main competitors?

Direct peers on record are MED-EL, Cochlear Limited and Oticon Medical (Demant). Broad incumbents are Demant, Starkey Hearing Technologies, WS Audiology (Signia / Widex), GN Hearing (GN Audio) and Phonak (Sonova). Envoy Medical is listed as an emerging player. Spiral Therapeutics is listed as an others.

Does Advanced Bionics have an API?

No public API is recorded for Advanced Bionics.

What industry is Advanced Bionics in?

Advanced Bionics's product category is Cochlear Implants. Its primary akta.pro industry code is CRACANAL, Hearing Enhancement / Assistive Listening Audio Devices. Its NAICS code is 334510 and its SIC code is 3845.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
WsjHealth Care Roundup: Market TalkJefferies analyst David Stanton said Advanced Bionics' Integro CI sound processor could modestly constrain Cochlear's share in selected European markets. He sees it as supporting gradual market-share stabilization or gains for Sonova, not rapid losses for Cochlear. Jefferies holds Cochlear with a target price of A$144.75.FinancialContent Business PageAdvanced Bionics Announces FDA Approval of Expanded Cochlear Implant Inclusion Criteria for Patients with Single-Sided Deafness and Asymmetric Hearing LossAdvanced Bionics announced expanded U.S. FDA indications for its cochlear implant systems, extending eligibility to more adult and pediatric patients with single-sided deafness or asymmetric hearing loss. The expanded criteria include specific audiometric thresholds of 80 dB HL for adults (90 dB HL for children) in the poorer-hearing ear and CNC word recognition scores of 20% or less, representing the broadest candidacy range in the industry. With an estimated 271,000 to 345,000 U.S. adults affected by single-sided deafness and current cochlear implant utilization at only 2.1% of eligible candidates, the approval opens substantial new market access for the company.MorningstarAdvanced Bionics Announces FDA Approval of Expanded Cochlear Implant Inclusion Criteria for Patients with Single-Sided Deafness and Asymmetric Hearing LossAdvanced Bionics announced expanded FDA indications for its cochlear implant systems, broadening eligibility for adults and children with single-sided deafness or asymmetric hearing loss. The criteria set pure-tone average thresholds of 80 dB HL for adults and 90 dB HL for children, with a 15 dB interaural difference. The company estimates 271,000 to 345,000 U.S. adults with single-sided deafness, with cochlear implant utilization at only 2.1%.The Hearing ReviewAdvanced Bionics Announces Research Collaboration with Spiral TherapeuticsAdvanced Bionics (AB), a developer of cochlear implant technology and subsidiary of Sonova Group, has announced an equity investment and research collaboration with Spiral Therapeutics to explore integrating Spiral's drug-delivery platform with AB's cochlear implant development. The partnership will focus on investigating how Spiral's platform, designed for minimally invasive and precise delivery of therapeutics to the cochlea, could be utilized during cochlear implant surgery to address unmet needs in the field. The collaboration represents an early-stage R&D effort combining both companies' complementary capabilities for potential future patient benefits.Pulse 2.0Spiral Therapeutics: $27 Million Series B And Advanced Bionics Partnership Advance Inner Ear TherapiesSpiral Therapeutics announced the close of a $27 million Series B financing round led by Gund Investment, with participation from Advanced Bionics and continued backing from Ferring Ventures and Uni-Bio Science Group. Concurrent with the funding, Spiral entered into a strategic R&D collaboration with Advanced Bionics to explore sustained local drug delivery at the time of cochlear implantation. The proceeds will support advancement of Spiral's lead candidate SPT-2101, which has demonstrated statistically significant reduction in vertigo among Ménière's disease patients, and further development of its MICS drug delivery platform.YahooSpiral Therapeutics Announces $27 Million Series B Financing and Strategic Partnership with Advanced BionicsSpiral Therapeutics, a clinical-stage company developing therapies for inner ear disorders, closed a $27 million Series B financing round led by Gund Investment, with new strategic participation from Advanced Bionics and a major global pharmaceutical company alongside existing investors Ferring Ventures and Uni-Bio Science Group. Concurrent with the financing, Spiral entered into a strategic R&D collaboration with Advanced Bionics to develop sustained local drug delivery at the time of cochlear implantation to improve outcomes for recipients. The proceeds will support advancement of Spiral's lead program SPT-2101, which demonstrated statistically significant reduction in vertigo for Ménière's disease patients and is preparing for a registrational trial, as well as expansion of the MICS™ drug delivery platform.PR NewswireSpiral Therapeutics Announces $27 Million Series B Financing and Strategic Partnership with Advanced BionicsSpiral Therapeutics, a clinical-stage biotech focused on inner ear disorders, closed a $27 million Series B financing round led by Gund Investment, with new strategic participation from Advanced Bionics and an unnamed major global pharmaceutical company. Concurrent with the financing, Spiral entered an R&D collaboration with Advanced Bionics to develop sustained local drug delivery solutions for cochlear implant recipients. Proceeds will fund the registrational trial for lead program SPT-2101, which demonstrated statistically significant vertigo reduction in Ménière's disease patients, and expansion of the proprietary MICS drug delivery platform.Venture Capital Access OnlineSpiral Therapeutics Announces $27 Million Series B Financing and Strategic Partnership with Advanced BionicsSpiral Therapeutics closed a $27 million Series B financing led by Gund Investment, with Advanced Bionics and a major pharmaceutical company joining as strategic investors. The company also entered an R&D collaboration with Advanced Bionics to explore drug delivery at cochlear implantation. Proceeds will support its pipeline, including SPT-2101 and the MICS platform.TechStartupsSecurity Risk Advisors Purple Team Participants Can Now Earn CPE CreditsSecurity Risk Advisors announced that its Purple Team exercises now earn CPE credits from GIAC and ISC2. Each 15-hour engagement yields up to 15 CPE credits per participant, with certificates issued from April 2026. Participants must attend at least 80% of sessions.TechStartupsAmazon acquires Globalstar for $11.6B, taking direct aim at SpaceX’s StarlinkAmazon agreed to acquire satellite operator Globalstar for about $11.57 billion, integrating its operations into its Leo satellite internet program. The deal, expected to close in 2027, gives Amazon control of Globalstar's spectrum and infrastructure, aiming to roll out direct-to-device connectivity by 2028. The acquisition puts Amazon on a direct collision course with SpaceX's Starlink, which leads the market.